Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Esperion Therapeutics Inc shares valued at $3,275 were purchased by Looker Benjamin on Oct 17 ’25. At $2.62 per share, Looker Benjamin acquired 1,248 shares.
Also, Looker Benjamin sold 6,267 shares, netting a total of over 17,573 in proceeds. Following the sale of shares at $2.80 each, the insider now holds 393,670 shares.
Before that, Koenig Sheldon L. had sold 28,427 shares from its account. In a trade valued at $79,254, the President and CEO traded Esperion Therapeutics Inc shares for $2.79 each. Upon closing the transaction, the insider’s holdings decreased to 28,427 shares, worth approximately $6.0 million.
As published in their initiating research note from Piper Sandler on November 25, 2025, Esperion Therapeutics Inc [ESPR] has been an Overweight and the price target has been revised to $9. Analysts at Goldman started covering the stock with ‘”a Neutral”‘ outlook in a report released in mid December. As of December 17, 2024, Cantor Fitzgerald has initiated its “an Overweight” rating for ESPR. Earlier on June 20, 2024, BofA Securities downgraded its rating. Their new recommendation was “an Underperform” for ESPR stock which previously was a “a Neutral”.
Analyzing ESPR Stock Performance
On last trading session, Esperion Therapeutics Inc [NASDAQ: ESPR] rose 7.05% to $3.95. The stock’s lowest price that day was $3.64, but it reached a high of $4.0189 in the same session. During the last five days, there has been a surge of approximately 41.58%. Over the course of the year, Esperion Therapeutics Inc shares have jumped approximately 56.75%. Shares of the company reached a 52-week high of $4.02 on 11/26/25 and a 52-week low of $0.69 on 05/15/25.
Support And Resistance Levels for Esperion Therapeutics Inc (ESPR)
According to the 24-hour chart, there is a support level at 3.72, which, if violated, would cause prices to drop to 3.49. In the upper region, resistance lies at 4.10. The next price resistance is at 4.25. RSI (Relative Strength Index) is 74.33 on the 14-day chart, showing overbought technical sentiment.
Is Esperion Therapeutics Inc subject to short interest?
Stocks of Esperion Therapeutics Inc saw a sharp rise in short interest on 2025-11-14 jumping by 0.54 million shares to 24.96 million. Data from Yahoo Finance shows that the short interest on 2025-10-15 was 24.42 million shares. A jump of 2.17% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 4.16 of the overall float, the days-to-cover ratio (short ratio) jumped to 4.16.
Which companies own the most shares of Esperion Therapeutics Inc (ESPR)?
In terms of Esperion Therapeutics Inc share price expectations, FactSet research, analysts set an average price target of 9 in the next 12 months, up nearly 143.9% from the previous closing price of $3.69. Analysts anticipate Esperion Therapeutics Inc stock to reach 9 by 2025, with the lowest price target being 9. In spite of this, 8 analysts ranked Esperion Therapeutics Inc stock as Buy at the end of 2025.
